Seasonal Changes in Body Composition and Blood HbA1c Levels Without Weight Change in Male Patients With Type 2 Diabetes Treated With Insulin

Sohmiya, Motoi; Kanazawa, Ippei; Kato, Yuzuru

doi:10.2337/diacare.27.5.1238

Cited by 63 publications

(50 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The agents that were administered until just before the initiation of sitagliptin or concomitantly during the study period might have influenced the ΔHbA1c at 24 and 3 months. In Japanese patients with type 2 diabetes, HbA1c levels are seen to fluctuate according to the season (usually decreasing from spring to summer and increasing from autumn to winter) (27,28). Therefore, seasonal fluctuations might have exerted a greater influence on ΔHbA1c at 3 months than ΔHbA1c at 24 months because of the different sitagliptin start dates.…”

Section: Discussionmentioning

confidence: 99%

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

et al. 2015

View full text Add to dashboard Cite

Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of ! 700 days from the initiation of sitagliptin treatment and the measurement of hemoglobin A1c (HbA1c) had been performed at 0, 3, 6, 12, 18, and 24 months after the initiation of treatment. From the population of 616 patients, 447 and 169 had received sitagliptin for ! 700 and <700 days, respectively. The primary endpoint was ΔHbA1c at 24 months. The factors associated with the hypoglycemic effect of sitagliptin were also investigated. Results Sitagliptin treatment significantly decreased the level of HbA1c, and the hypoglycemic effect was sustained for at least 2 years. The baseline HbA1c level, duration of diabetes, Δbody weight value, and ΔHbA1c value at 3 months were independently associated with the hypoglycemic effect of sitagliptin. Conclusion Sitagliptin has a long-term hypoglycemic effect in type 2 diabetes patients. A patient's ΔHbA1c at 3 months may be a predictor of their ΔHbA1c at 24 months.

show abstract

Section: Discussionmentioning

confidence: 99%

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…potentiating insulin resistance). Moreover, it must be appreciated that this seasonal mechanism for regulating metabolism that has been preserved over hundreds of millions of years of evolution is also manifested in man, as multiple studies have clearly demonstrated [66][67][68][69][70][71][72][73][74][75].…”

Section: Role Of the Biological Clock (Scn) And Circadian Rhythms In mentioning

confidence: 99%

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

Raskin

Cincotta

2016

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

An extended series of studies indicate that endogenous phase shifts in circadian neuronal input signaling to the biological clock system centered within the hypothalamic suprachiasmatic nucleus (SCN) facilitates shifts in metabolic status. In particular, a diminution of the circadian peak in dopaminergic input to the peri-SCN facilitates the onset of fattening, insulin resistance and glucose intolerance while reversal of low circadian peak dopaminergic activity to the peri-SCN via direct timed dopamine administration to this area normalizes the obese, insulin resistant, glucose intolerant state in high fat fed animals. Systemic circadian-timed daily administration of a potent dopamine D2 receptor agonist, bromocriptine, to increase diminished circadian peak dopaminergic hypothalamic activity across a wide variety of animal models of metabolic syndrome and type 2 diabetes mellitus (T2DM) results in improvements in the obese, insulin resistant, glucose intolerant condition by improving hypothalamic fuel sensing and reducing insulin resistance, elevated sympathetic tone, and leptin resistance. A circadian-timed (within 2 hours of waking in the morning) once daily administration of a quick release formulation of bromocriptine (bromocriptine-QR) has been approved for the treatment of T2DM by the U.S. Food and Drug Administration. Clinical studies with such bromocriptine-QR therapy (1.6 to 4.8 mg/day) indicate that it improves glycemic control by reducing postprandial glucose levels without raising plasma insulin. Across studies of various T2DM populations, bromocriptine-QR has been demonstrated to reduce HbA1c by -0.5 to -1.7. The drug has a good safety profile with transient mild to moderate nausea, headache and dizziness as the most frequent adverse events noted with the medication. In a large randomized clinical study of T2DM subjects, bromocriptine-QR exposure was associated with a 42% hazard ratio reduction of a pre-specified adverse cardiovascular endpoint including myocardial infarction, stroke, hospitalization for congestive heart failure, revascularization surgery, or unstable angina. Bromocriptine-QR represents a novel method of treating T2DM that may have benefits for cardiovascular disease as well. ARTICLE HISTORY

show abstract

“…80 Winter increases in body fat, plasma HbA1c (glycated haemoglobin, a marker of average blood glucose levels) and insulin resistance were observed in Japanese patients with insulin-treated type-2 diabetes. 81 Most studies have found that the incidence of type-2 diabetes is lowest in summer, 82 with a concurrent nadir in fasting glucose;…”

Section: Seasonal Effectsmentioning

confidence: 99%

Ultraviolet radiation, vitamin D and the development of obesity, metabolic syndrome and type-2 diabetes

Gorman

Lucas

Allen-Hall

et al. 2017

Photochem Photobiol Sci

View full text Add to dashboard Cite

show abstract

Seasonal Changes in Body Composition and Blood HbA1c Levels Without Weight Change in Male Patients With Type 2 Diabetes Treated With Insulin

Cited by 63 publications

References 3 publications

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

Ultraviolet radiation, vitamin D and the development of obesity, metabolic syndrome and type-2 diabetes

Contact Info

Product

Resources

About